Long-term multicentre randomised controlled study of high frequency chest wall oscillation versus positive expiratory pressure mask in cystic fibrosis

Thorax

Volumn 68, Issue 8, 2013, Pages 746-751

  McIlwaine, Maggie Patricia ^a   Alarie, Nancy ^b   Davidson, George F ^a   Lands, Larry C ^b   Ratjen, Felix ^c   Milner, Ruth ^d   Owen, Blythe ^c   Agnew, Jennifer L ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MONTREAL CHILDREN S HOSPITAL   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CANADA; CHEST WALL OSCILLATION; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE EXACERBATION; FEMALE; HIGH FREQUENCY CHEST WALL OSCILLATION; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT SATISFACTION; POSITIVE EXPIRATORY PRESSURE MASK THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; THERAPY; THERAPY EFFECT; TREATMENT DURATION;

CYSTIC FIBROSIS; HEALTH ECONOMIST;

ADOLESCENT; ADULT; CHEST WALL OSCILLATION; CHILD; CYSTIC FIBROSIS; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; LARYNGEAL MASKS; MALE; MIDDLE AGED; POSITIVE-PRESSURE RESPIRATION; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84879964709     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2012-202915     Document Type: Article

References (33)

1. Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 2004;23:146 -58.
2. Davis PB, Drumm M, Konstan MW. State of the art: cystic fibrosis. Am J Respir Crit Care Med 1996;154:1229-56.
3. Flume PA, Robinson KA, O'Sullivan BP, et al. Clinical practice guidelines for pulmonary therapies committee. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care 2009;54:522-37.
4. Bott J, Blumenthal S, Buxton M, et al. Guidelines for the physiotherapy management of the adult, medical, spontaneously breathing patient. Thorax 2009;64:1-52.
5. International Physiotherapy Group for Cystic Fibrosis. Physiotherapy in the treatment of cystic fibrosis. 4th edn. 2009. Cystic Fibrosis Worldwide. http://www.cfww.org (accessed January 29 2013).
6. McIlwaine M, Agnew J, Black C. Use of airway clearance techniques in cystic fibrosis clinics in Canada [abstract]. Pediatr Pulmonol 2008;43(Suppl 31):P392.
7. McIlwaine PM, Wong LTK, Peacock D, et al. Long-term comparative trial of conventional postural drainage and percussion versus positive expiratory pressure physiotherapy in the treatment of cystic fibrosis. J Pediatr 1997;131:570-4. (Pubitemid 28006931)
8. Gaskin L, Corey M, Shin J, et al . Long-term trial of conventional postural drainage and percussion versus positive expiratory pressure [abstract]. Pediatr Pulmonol 1998;26(Suppl 17):p345.
9. Hansen LG, Warwick WJ, Hansen KL. Mucus transport mechanisms in relation to the effect of high frequency chest compression (HFCC) on mucus clearance. Pediatr Pulmonol 1994;17:113-18.
10. Dasgupta B, Brown NE, King M. Effects of sputum oscillations and rhDNase in vitro: a combined approach to treat cystic fibrosis lung disease. Pediatr Pulmonol 1998;26:250-5. (Pubitemid 28492285)
11. Morrison L, Agnew J. Oscillating devices for airway clearance in cystic fibrosis. Cochrane Cystic Fibrosis and Genetic Disorders Group. Cochrane Database Syst Rev 2009;(1):CD006842.
12. Milla CE, Hansen LG, Weber A, et al. High-frequency chest compression: effect of the third generation compression waveform. Biomed Instrum Technol 2004;38:322-8. (Pubitemid 39050577)
13. Saiman L, Anstead M, Mayer-Hamblett N, et al . Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa. A randomized controlled trial. JAMA 2010;303:1707-15.
14. Treggiari MM, Rosenfeld M, Mayer-Hamblett N, et al. EPIC Study Group. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study. Contemp Clin Trials 2009;30:256-68.
15. American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 1995;152;1107-36.
16. Stanojevic S, Wade A, Stocks J, et al. Reference ranges for spirometry across all ages. Am J Respir Crit Care Med 2008;177:253-60. (Pubitemid 351198367)
17. Quittner AL, Buu A, Messer MA, et al. Development and validation of the cystic fibrosis questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest 2005;128:2347-54. (Pubitemid 41507578)
18. Quittner AL, Buu A, Watrous M, et al. Cystic Fibrosis Questionnaire: A Health-Related Quality of Life Measure. User Manual English Version 2.0. The Cystic Fibrosis Foundation and Genentech, 2000.
19. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-40. (Pubitemid 43113028)
20. Bendiak GN, Ratjen F. The approach to Pseudomonas aeruginosa in cystic fibrosis. Semin Respir Crit Care Med 2009;30:587-95.
21. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637-42. (Pubitemid 24276863)
22. Quittner AL, Modi AC, Wainwright C, et al. Determination of the minimal clinically important difference scores for the cystic fibrosis questionnaire-revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135:1610-18.
23. Mayer-Hamblett N, Ramsey BW, Kronmal RA. Advancing outcome measures for the new era of drug development in cystic fibrosis. Am Thorac Soc 2007;4:370-7. (Pubitemid 47330874)
24. Waters V, Stanojevic S, Eshetu G, et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J 2012;40:61-6.
25. Warwick WE, Hansen LG. The long-term effect of high frequency chest compression therapy on pulmonary complications of cystic fibrosis. Pediatr Pulmonol 1991;11:265-71.
26. Arenas GD, Olin KJ, Vega J, et al. Comparison of high frequency chest compression and conventional chest physiotherapy in hospitalized patients with cystic fibrosis. Am J Respir Crit Care Med 1994;150:1154-7. (Pubitemid 24318051)
27. Braggion C, Appellate LM, Cornacchia M, et al. Short-term effects of three chest physiotherapy regimens in patients hospitalized for pulmonary exacerbations of cystic fibrosis: across-over randomized trial. Pediatr Pulmonol 1995;19:16-22.
28. Oermann CM, Sockrider MM, Giles D, et al. Comparison of high frequency chest wall oscillation and oscillating positive expiratory pressure in the home management of cystic fibrosis: a pilot study. Pediatr Pulmonol 2001;22:372-7. (Pubitemid 33015654)
29. Varekojiss SM, Douce FH, Flucke RL, et al. A comparison of the therapeutic effectiveness of and preference for postural drainage and percussion, intrapulmonary percussive ventilation, and high frequency chest wall compression in hospitalized cystic fibrosis patients. Respir Care 2003;48:24-8. (Pubitemid 47372068)
30. Phillips GE, Pike SE, Jaffe A, et al. Comparison of active cycle of breathing and high frequency oscillation jacket in children with cystic fibrosis. Pediatr Pulmonol 2004;37:71-5. (Pubitemid 38030074)
31. Osman LP, Roughton M, Hodson ME, et al. Short-term comparative study of high frequency chest wall oscillation and European airway clearance techniques in patients with cystic fibrosis. Thorax 2010;65:196-200.
32. Sontag MK, Quittner AL, Modi AC, et al. Lessons learned from a randomized trial of airway secretion clearance techniques in cystic fibrosis. Pediatr Pulmonol 2010;45:291-300.
33. Modi AC, Cassedy AE, Quittner AL, et al. Trajectories of adherence to airway clearance therapy for patients with cystic fibrosis. J Pediatr Psychol 2010;35:1028-37.